ClinicalTrials.gg
RecruitingNCT07463001Updated Oct 15, 2026

Optimization and Testing Effectiveness of a Collaborative Intervention for School Attendance Problems in Norwegian Municipalities

An interventional study of Back2School in School Attendance Problems, sponsored by Norwegian University of Science and Technology. Recruiting at 4 sites in Norway. Open to participants aged 9 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
9 Years to 15 Years
Sex
All
01

Study summary

In this study we will investigate the effects of an intervention called Back2School, revised and adapted for Norwegian conditions on school attendance. A total of 240 participants will be recruited. All participants who have been enrolled will receive the intervention. Half of the participants will receive the intervention without delay (the experiment group), and the other half will receive it following a 13-week period (the control group). Following consent, screening for eligibility and randomization, the intervention will start with an assessment related to the individual participant and condition at the participants' school. Based on this a shared understanding and an intervention plan is developed. Over a 13-week period the youth, the family and the school, work together guided by the municipal team to increase attendance and solve problems related to this. Assessments will be carried out after the intervention and 6 months later.

02

Conditions studied

  • School Attendance Problems

Keywords

  • School attendance problems
  • Back2School
  • Norway
  • Randomized controlled trial
  • Cognitive Behavioral Therapy
  • Children and adolescents
03

In context

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be between the ages of 9 and 15 at the time of enrollment.
  2. Participants must have less than 80% attendance for the last 12 weeks of school at the time of screening.
  3. At least one parent has to talk and understand Norwegian.
  4. At least one parent has to be motivated to participate.
  5. The school must agree to participate in the intervention

Exclusion criteria

Exclusion Criteria:

1 The participant has a known diagnosis of autism-spectrum disorder, psychosis, and/or eating disorder.

2. Participant needs acute psychiatric intervention.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Direct intervention

    Participants randomized to this intervention will receive the 13 week intervention Back2School starting immediately after randomization.

    Behavioral: Back2School

  • Other
    Delayed intervention/ Wait list control

    Participants randomized to delayed intervention will ha to wait for 13-15 weeks following randomization before the intervention is started. During the waiting phase they can receive treatment as usual

    Behavioral: Back2School

Interventions

  • BehavioralBack2School

    The revised Back2S school manual consists of an initial assessment, a case formulation conference, 16 sessions and 3 meetings with different participants (parents, youth, school personnel) over 13 weeks. There is a booster session 12 weeks after the final session and one 24 weeks after the final session.

06

What researchers measure

Primary outcomes

  1. School attendance

    School attendance measured on a daily basis by teacher.

    Time frame: Direct: Avg at Baseline, 2 weeks at end (13 weeks from baseline), 2 weeks at 6 months (37 w from baseline) Delayed: Avg at baseline, 2 weeks before start (13 w from baseline) 2 weeks at end (28 w from baseline), 2 weeks at 6 months (54 w from baseline)

  2. General functioning

    Impact on daily life as measured by the SDQ impact scale

    Time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3)

Secondary outcomes

  1. Change in Quality of life

    Measures perceived quality of life as reported by parents and child using Kidscreen 10

    Time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3)

  2. Change in symptoms of anxiety

    Measures change in symptoms of anxiety as measured by the SCAS reported by parents and child

    Time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3)

  3. Change in symptoms of Depression

    Change in symptoms of depression reported by child and parents using the SMFQ

    Time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3)

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Not allowed by Norwegian law and therefore not allowed by our ethical board

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Apr 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 10, 2026
StartActual
Apr 10, 2026was Mar 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Mar 1, 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • NORCE, RKBU Vest · Bergen, Norwayno status→Recruiting
  • Pilar, Regionsenter for barn og unges psykiske helse · Oslo, Norwayno status→Recruiting
  • UIT, RKBU Nord · Tromsø, Norwayno status→Recruiting
  • Norwegian University of Scinece and Technology · Trondheim, Norwayno status→Recruiting
Oct 15, 2026
Start date
Mar 23, 2026→Apr 10, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • NORCE, RKBU Vest · Bergen, Norwayno status→Recruiting
    • Pilar, Regionsenter for barn og unges psykiske helse · Oslo, Norwayno status→Recruiting
    • UIT, RKBU Nord · Tromsø, Norwayno status→Recruiting
    • Norwegian University of Scinece and Technology · Trondheim, Norwayno status→Recruiting
    Start date Mar 23, 2026→Apr 10, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07463001
Collaborators
The Research Council of Norway, University of Tromso, University of Bergen, Regionsenter for barn og unges psykiske helse, Regionalt kunnskapssenter for barn og unge - Nord, NORCE Norwegian Research Centre AS, University of Stavanger, University of Aarhus
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Apr 10, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Jo M Ingul, phd
Contact
jo.m.ingul@ntnu.no
+4792869163
Kristin Ytreland, phd
Contact
kristin.ytreland@ntnu.no
Jo Magne Ingul, phd
principal investigator · Norwegian University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion